BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2025 8:38:07 AM | Browse: 397 | Download: 357
 |
Received |
|
2025-05-28 09:57 |
|
Peer-Review Started |
|
2025-05-28 09:58 |
|
First Decision by Editorial Office Director |
|
2025-06-11 03:35 |
|
Return for Revision |
|
2025-06-11 03:35 |
|
Revised |
|
2025-06-23 17:26 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-08-05 02:45 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-08-06 01:50 |
|
Articles in Press |
|
2025-08-06 01:50 |
|
Edit the Manuscript by Language Editor |
|
2025-08-20 09:55 |
|
Typeset the Manuscript |
|
2025-09-01 08:23 |
|
Publish the Manuscript Online |
|
2025-09-15 08:38 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhao Gao, Zheng-Fei Zhou, Xiao-Yan Wang, Tao Song, Shi-Kai Wu and Xuan Jin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital) |
No. 2022CR65 |
|
| Corresponding Author |
Xuan Jin, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. 27051079@qq.com |
| Key Words |
Microsatellite stable; Metastatic colorectal cancer; Immune checkpoint inhibitors; Programmed death 1 |
| Core Tip |
This study aims to evaluate the effectiveness of chemoimmunotherapy (CIT) as the first-line regimen for microsatellite stable metastatic colorectal cancer verses standard-of-care therapy (5-fluorouracil/leucovorin/oxaliplatin/bevacizumab) in the real world. The efficacy of CIT in microsatellite stable metastatic colorectal cancercould potentially surpass that of standard first-line chemotherapy protocols. Further research is needed to investigate specific clinical characteristics or biomarkers to identify patients who may derive benefit from CIT approaches. |
| Publish Date |
2025-09-15 08:38 |
| Citation |
Gao Z, Zhou ZF, Wang XY, Song T, Wu SK, Jin X. Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis. World J Gastrointest Oncol 2025; 17(9): 109949 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i9/109949.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i9.109949 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
